FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890556710> ?p ?o ?g. }

• W2890556710 endingPage "92" @default.
• W2890556710 startingPage "86" @default.
• W2890556710 abstract "Objectives EGFR-mutated or ALK-rearranged non-small cell lung cancer (NSCLC) often showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports exist with integrated analysis, to interpret the underlying mechanism of poor response to PD-1/PD-L1 inhibitors. We have retrospectively analyzed the tumor microenvironment (TME) based on tumor PD-L1 expression and CD8+ T cells infiltration in patients with EGFR mutations and ALK rearrangements, and the prognostic value of TME subtypes on overall survival (OS). Materials and methods Tumor samples from 715 patients with lung cancer were retrospectively collected at Guangdong Lung Cancer Institute. Tumoral PD-L1 expression (N = 715) and CD8+ T cells infiltration (N = 658) was determined by immunohistochemistry (IHC), based on which TME was categorized into four different subtypes: PD-L1+/CD8+, PD-L1-/CD8+, PD-L1+/CD8-, PD-L1-/CD8-. Proportion of four TME subtypes was determined, and overall survival with PD-L1 expression and TME was analyzed. Results In patients with EGFR mutations or ALK rearrangements, proportion of PD-L1+/CD8+ tumors was the lowest (5.0%, 17/342), and that of PD-L1-/CD8- tumors was the highest (63.5%, 217/342). In patients with wild-type EGFR and ALK, 14.2% (45/316) tumors were PD-L1+/CD8+ and 50.3% (159/316) tumors were PD-L1-/CD8- (P < 0.001). Median OS of EGFR-mutated or ALK-rearranged lung cancer was 78.6 months in PD-L1 positive group and 93.4 months in PD-L1 negative group (HR 0.47, 95%CI 0.23-0.76, P = 0.005). PD-L1+/CD8+ group exhibited the shortest OS, with 44.3 months, but is likely to respond to CPIs. The PD-L1-/CD8+ group exhibited the longest OS but is unlikely to respond to CPIs. Conclusion Patients with EGFR mutations or ALK rearrangements exhibited lower PD-L1 and CD8 co-expression level in TME, which could be responsible for poor response to CPIs. PD-L1 and CD8 co-expression in EGFR-mutated or ALK-rearranged lung cancer is a biomarker for poor prognosis with shorter OS." @default.
• W2890556710 created "2018-09-27" @default.
• W2890556710 creator A5004598929 @default.
• W2890556710 creator A5014646073 @default.
• W2890556710 creator A5014800253 @default.
• W2890556710 creator A5016050402 @default.
• W2890556710 creator A5043568223 @default.
• W2890556710 creator A5057744043 @default.
• W2890556710 creator A5068967911 @default.
• W2890556710 creator A5072012669 @default.
• W2890556710 creator A5074151953 @default.
• W2890556710 creator A5075403547 @default.
• W2890556710 creator A5075426616 @default.
• W2890556710 creator A5078864277 @default.
• W2890556710 creator A5082411167 @default.
• W2890556710 creator A5083650470 @default.
• W2890556710 creator A5089732639 @default.
• W2890556710 date "2018-11-01" @default.
• W2890556710 modified "2023-10-18" @default.
• W2890556710 title "Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer" @default.
• W2890556710 cites W1889335134 @default.
• W2890556710 cites W1981876938 @default.
• W2890556710 cites W2071865120 @default.
• W2890556710 cites W2145411470 @default.
• W2890556710 cites W2279684443 @default.
• W2890556710 cites W2293531514 @default.
• W2890556710 cites W2340636398 @default.
• W2890556710 cites W2400514548 @default.
• W2890556710 cites W2486637311 @default.
• W2890556710 cites W2488061344 @default.
• W2890556710 cites W2560357239 @default.
• W2890556710 cites W2561459036 @default.
• W2890556710 cites W2567564314 @default.
• W2890556710 cites W2569464488 @default.
• W2890556710 cites W2578528809 @default.
• W2890556710 cites W2591374950 @default.
• W2890556710 cites W2606022415 @default.
• W2890556710 cites W2617513002 @default.
• W2890556710 cites W2626831245 @default.
• W2890556710 cites W2728491028 @default.
• W2890556710 cites W2731960689 @default.
• W2890556710 cites W2736856431 @default.
• W2890556710 cites W2737044461 @default.
• W2890556710 cites W2737082469 @default.
• W2890556710 cites W2761575992 @default.
• W2890556710 cites W2766425839 @default.
• W2890556710 cites W2768053061 @default.
• W2890556710 cites W2768621814 @default.
• W2890556710 cites W2791290180 @default.
• W2890556710 cites W2949273159 @default.
• W2890556710 doi "https://doi.org/10.1016/j.lungcan.2018.09.010" @default.
• W2890556710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30429043" @default.
• W2890556710 hasPublicationYear "2018" @default.
• W2890556710 type Work @default.
• W2890556710 sameAs 2890556710 @default.
• W2890556710 citedByCount "57" @default.
• W2890556710 countsByYear W28905567102019 @default.
• W2890556710 countsByYear W28905567102020 @default.
• W2890556710 countsByYear W28905567102021 @default.
• W2890556710 countsByYear W28905567102022 @default.
• W2890556710 countsByYear W28905567102023 @default.
• W2890556710 crossrefType "journal-article" @default.
• W2890556710 hasAuthorship W2890556710A5004598929 @default.
• W2890556710 hasAuthorship W2890556710A5014646073 @default.
• W2890556710 hasAuthorship W2890556710A5014800253 @default.
• W2890556710 hasAuthorship W2890556710A5016050402 @default.
• W2890556710 hasAuthorship W2890556710A5043568223 @default.
• W2890556710 hasAuthorship W2890556710A5057744043 @default.
• W2890556710 hasAuthorship W2890556710A5068967911 @default.
• W2890556710 hasAuthorship W2890556710A5072012669 @default.
• W2890556710 hasAuthorship W2890556710A5074151953 @default.
• W2890556710 hasAuthorship W2890556710A5075403547 @default.
• W2890556710 hasAuthorship W2890556710A5075426616 @default.
• W2890556710 hasAuthorship W2890556710A5078864277 @default.
• W2890556710 hasAuthorship W2890556710A5082411167 @default.
• W2890556710 hasAuthorship W2890556710A5083650470 @default.
• W2890556710 hasAuthorship W2890556710A5089732639 @default.
• W2890556710 hasConcept C121608353 @default.
• W2890556710 hasConcept C126322002 @default.
• W2890556710 hasConcept C142724271 @default.
• W2890556710 hasConcept C143998085 @default.
• W2890556710 hasConcept C167672396 @default.
• W2890556710 hasConcept C203014093 @default.
• W2890556710 hasConcept C204232928 @default.
• W2890556710 hasConcept C2776107976 @default.
• W2890556710 hasConcept C2776256026 @default.
• W2890556710 hasConcept C2777701055 @default.
• W2890556710 hasConcept C2777714996 @default.
• W2890556710 hasConcept C2778326572 @default.
• W2890556710 hasConcept C2781053074 @default.
• W2890556710 hasConcept C502942594 @default.
• W2890556710 hasConcept C71924100 @default.
• W2890556710 hasConcept C8891405 @default.
• W2890556710 hasConceptScore W2890556710C121608353 @default.
• W2890556710 hasConceptScore W2890556710C126322002 @default.
• W2890556710 hasConceptScore W2890556710C142724271 @default.
• W2890556710 hasConceptScore W2890556710C143998085 @default.
• W2890556710 hasConceptScore W2890556710C167672396 @default.

• next